Neil P Shah

Neil P Shah

UNVERIFIED PROFILE

Are you Neil P Shah?   Register this Author

Register author
Neil P Shah

Neil P Shah

Publications by authors named "Neil P Shah"

Are you Neil P Shah?   Register this Author

86Publications

2690Reads

48Profile Views

NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.

Authors:
Neil P Shah

J Natl Compr Canc Netw 2019 May;17(5.5):611-613

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.5013DOI Listing
May 2019

Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.

Authors:
Neil P Shah

J Clin Oncol 2018 01 5;36(3):220-224. Epub 2017 Dec 5.

Neil P. Shah, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4663DOI Listing
January 2018

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells.

Sci Rep 2017 06 30;7(1):4447. Epub 2017 Jun 30.

Department of Pediatrics, Division of Hem/Onc/BMT, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-04796-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493614PMC
June 2017

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J Natl Compr Canc Netw 2016 12;14(12):1505-1512

From St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Duke Cancer Institute; Roswell Park Cancer Institute; University of Colorado Cancer Center; University of Michigan Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; UCSF Helen Diller Family Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Wisconsin Carbone Cancer Center; National Comprehensive Cancer Network; Huntsman Cancer Institute at the University of Utah; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0162DOI Listing
December 2016

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

J Clin Oncol 2016 07 23;34(20):2333-40. Epub 2016 May 23.

Jorge E. Cortes and Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center, Houston, TX; Neil P. Shah, University of California San Francisco School of Medicine, San Francisco, CA; Brigid Bradley-Garelik and George Manos, Bristol-Myers Squibb, Princeton, NJ; Giuseppe Saglio, University of Turin, Turin; Michele Baccarani, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; Jiří Mayer, University Hospital Brno and Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Concepción Boqué, Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore; Luis Casanova, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú;and Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118045PMC
July 2016

Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia.

Am Soc Clin Oncol Educ Book 2012 :685-9

From the Division of Hematology/Oncology, University of California, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.685DOI Listing
April 2016

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

Am Soc Clin Oncol Educ Book 2013 :313-8

From the Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.313DOI Listing
April 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

Am J Hematol 2015 Nov 12;90(11):1060-4. Epub 2015 Oct 12.

Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24174DOI Listing
November 2015

PPARγ: Welcoming the New Kid on the CML Stem Cell Block.

Cancer Cell 2015 Oct;28(4):409-411

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.09.017DOI Listing
October 2015

Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.

Sci Rep 2015 Sep 30;5:14538. Epub 2015 Sep 30.

Cincinnati Children's Hospital Medical Center, Cancer Blood Disease Institute, Divisions of Experimental Hematology and Cancer Pathology, Cincinnati, Ohio, 45229 USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/srep14538
Publisher Site
http://dx.doi.org/10.1038/srep14538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588578PMC
September 2015

Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

Eur J Med Chem 2015 Apr 28;94:123-31. Epub 2015 Feb 28.

College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ 85721, USA; The University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ 85724, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02235234150014
Publisher Site
http://dx.doi.org/10.1016/j.ejmech.2015.02.052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666306PMC
April 2015

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.

Elife 2014 Dec 22;3. Epub 2014 Dec 22.

Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States.

View Article

Download full-text PDF

Source
https://elifesciences.org/articles/03445
Publisher Site
http://dx.doi.org/10.7554/eLife.03445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307180PMC
December 2014

Integrating current treatment options for TKI-resistant chronic myeloid leukemia.

Clin Adv Hematol Oncol 2014 Jul;12(7 Suppl 13):3-17, 1

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
July 2014

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Nat Chem Biol 2014 Apr 2;10(4):305-12. Epub 2014 Mar 2.

1] Nuffield Department of Clinical Medicine, University of Oxford, Structural Genomics Consortium, Oxford, UK. [2] Nuffield Department of Clinical Medicine, University of Oxford, Target Discovery Institute (TDI), Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nchembio.1471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998711PMC
April 2014

Crenolanib is a selective type I pan-FLT3 inhibitor.

Proc Natl Acad Sci U S A 2014 Apr 12;111(14):5319-24. Epub 2014 Mar 12.

Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, and Division of Laboratory Medicine, University of California, San Francisco, CA 94143.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1320661111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986131PMC
April 2014

What does a deep molecular response signify?

J Clin Oncol 2014 Feb 2;32(5):471-4. Epub 2013 Dec 2.

Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.52.8307
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.52.8307DOI Listing
February 2014

MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.

Cancer Discov 2014 Feb 20;4(2):200-15. Epub 2013 Dec 20.

Departments of 1Pharmaceutical Sciences and Pharmacogenomics, 2Chemistry and Chemical Biology, 3Pharmaceutical Chemistry, 4Otolaryngology, and 5Epidemiology and Biostatistics; 6Division of Hematology/Oncology; and 7Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248023PMC
February 2014

Chronic Myelogenous Leukemia, Version 1.2014.

J Natl Compr Canc Netw 2013 Nov;11(11):1327-40

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105PMC
http://dx.doi.org/10.6004/jnccn.2013.0157DOI Listing
November 2013

Ins and outs of kinase DFG motifs.

Chem Biol 2013 Jun;20(6):745-6

KINOMEscan Division of DiscoveRx Corporation, 11180 Roselle Street, Suite D, San Diego, CA, 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2013.06.001DOI Listing
June 2013

Front-line TKI therapy for chronic-phase CML: the luxury of choice.

Authors:
Neil P Shah

Oncology (Williston Park) 2012 Oct;26(10):908, 910, 912

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.

View Article

Download full-text PDF

Source
October 2012

Sonography of supraspinatus tendon abnormalities in the neutral versus Crass and modified Crass positions: a prospective study.

J Ultrasound Med 2012 Aug;31(8):1203-8

New York–Presbyterian Hospital, Weill Cornell Medical Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7863/jum.2012.31.8.1203DOI Listing
August 2012

Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.

Hematology Am Soc Hematol Educ Program 2011 ;2011:121-7

Department of Hematology/Oncology, University of California-San Francisco, San Francisco, CA 94143-1270, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2011.1.121DOI Listing
April 2012

Advancing the STATus of MPN pathogenesis.

Blood 2012 Apr;119(15):3374-6

University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-406611DOI Listing
April 2012

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.

Authors:
Neil P Shah

Clin Adv Hematol Oncol 2011 Dec;9(12):925-6

Department of Hematology/Oncology, University of California-San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

Source
December 2011

Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.

Clin Cancer Res 2011 Nov 26;17(21):6605-7. Epub 2011 Sep 26.

Division of Hematology-Oncology, Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2240DOI Listing
November 2011

Fine-tuning targeted therapy of CML.

Authors:
Neil P Shah

Blood 2009 Dec;114(24):4914-5

University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-10-246371DOI Listing
December 2009

Loss of response to imatinib: mechanisms and management.

Authors:
Neil P Shah

Hematology Am Soc Hematol Educ Program 2005 :183-7

University of California - Los Angeles, 11-934 Louis Factor Building, Box 951678, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2005.1.183DOI Listing
November 2009

Medical management of CML.

Authors:
Neil P Shah

Hematology Am Soc Hematol Educ Program 2007 :371-5

University of California, San Francisco, Box 1270, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2007.1.371DOI Listing
July 2009

Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.

Cancer Res 2009 Mar 10;69(6):2384-92. Epub 2009 Mar 10.

Howard Hughes Medical Institute and Department of Molecular and Cell Biology, University of California, Berkely, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-3953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678021PMC
March 2009

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.

Cancer Cell 2008 Dec;14(6):485-93

Division of Hematology/Oncology, Department of Medicine, UCSF School of Medicine, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153561080800368
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2008.11.001DOI Listing
December 2008

Bench to bedside: BRCA: from therapeutic target to therapeutic shield.

Authors:
Neil P Shah

Nat Med 2008 May;14(5):495-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0508-495DOI Listing
May 2008

Advanced CML: therapeutic options for patients in accelerated and blast phases.

Authors:
Neil P Shah

J Natl Compr Canc Netw 2008 Mar;6 Suppl 2:S31-S36

Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California, 94143, USA.

View Article

Download full-text PDF

Source
March 2008

Progressive thoughts about progressive disease.

Authors:
Neil P Shah

Clin Cancer Res 2007 Sep;13(18 Pt 1):5229-31

Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0678DOI Listing
September 2007

Dasatinib.

Authors:
Neil P Shah

Drugs Today (Barc) 2007 Jan;43(1):5-12

Division of Hematology/Oncology, UCSF School of Medicine, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2007.43.1.1050791DOI Listing
January 2007

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.

Blood 2006 Jul 24;108(1):286-91. Epub 2006 Jan 24.

Division of Hematology/Oncology, The David Geffen School of Medicine at University of California-Los Angeles (UCLA, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-10-3969DOI Listing
July 2006

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Cancer Res 2006 Jan;66(2):1007-14

Departments of Molecular and Cell Biology and Chemistry, Howard Hughes Medical Institute, The University of California at Berkeley, Berkeley, CA 94720, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-2788DOI Listing
January 2006

Dynamics of chronic myeloid leukaemia.

Nature 2005 Jun;435(7046):1267-70

Program for Evolutionary Dynamics, Department of Organismic and Evolutionary Biology, Department of Mathematics, Harvard University, Cambridge, Massachusetts 02138, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature03669DOI Listing
June 2005

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Blood 2005 Mar 2;105(5):2093-8. Epub 2004 Sep 2.

Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-03-11
Publisher Site
http://dx.doi.org/10.1182/blood-2004-03-1114DOI Listing
March 2005

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

Proc Natl Acad Sci U S A 2005 Mar 10;102(9):3395-400. Epub 2005 Feb 10.

Molecular Biology Institute, Howard Hughes Medical Institute, and Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0409770102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC552942PMC
March 2005

Overriding imatinib resistance with a novel ABL kinase inhibitor.

Science 2004 Jul;305(5682):399-401

Division of Hematology and Oncology, Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1099480DOI Listing
July 2004

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.

Oncogene 2003 Oct;22(47):7389-95

Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206942DOI Listing
October 2003

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Proc Natl Acad Sci U S A 2002 Aug 29;99(16):10700-5. Epub 2002 Jul 29.

Center for Blood Research and Department of Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115-5717, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.162140299
Publisher Site
http://dx.doi.org/10.1073/pnas.162140299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC125018PMC
August 2002

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Cancer Cell 2002 Aug;2(2):117-25

Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(02)00096-xDOI Listing
August 2002